Lonza Completes Acquisition of Arch Chemicals
21 10월 2011 - 4:17AM
- Creation of the world's leading microbial control
business
- Customers will benefit from innovative microbial
control formulations based on a broad portfolio of registered and
approved active ingredients
- Integration of Arch as new business sector Microbial
Control
Lonza Group Ltd (SIX:LONN), one of the world's leading suppliers to
the life science industries, announced today the expiration of the
subsequent offering period of the tender offer by Lonza and its
indirect, wholly-owned subsidiary LG Acquisition Corp. for all
outstanding shares of common stock of Arch Chemicals, Inc.
(NYSE:ARJ) at a price of USD 47.20 per share in cash, without
interest and less any required withholding taxes.
The subsequent offering period expired at 12:00 midnight, New
York City time, on Wednesday, 19 October 2011. BNY Mellon
Shareowner Services, the depository for the tender offer, has
advised Lonza that, as of the expiration of the subsequent offering
period, a total of approximately 24,395,876 shares of Arch
Chemicals common stock were validly tendered and not properly
withdrawn pursuant to the tender offer during the initial offering
period and the subsequent offering period, representing
approximately 95.9% of the outstanding shares of Arch Chemicals
common stock. LG Acquisition Corp. has accepted for
payment all shares validly tendered and not properly withdrawn
pursuant to the tender offer during the initial offering period and
the subsequent offering period.
As a result of the tenders, Lonza will own more than 90 percent
of the outstanding shares of Arch Chemicals common stock and
expects to complete its acquisition of Arch Chemicals through a
short-form merger without a vote or meeting of Arch Chemicals'
shareholders. The short-form merger and completion of the
acquisition of Arch Chemicals is expected to be completed no later
than 21 October 2011. Upon completion of the merger, Arch Chemicals
will become an indirect, wholly-owned subsidiary of Lonza. In the
merger, each of the approximately 1,046,257 remaining shares of
Arch Chemicals common stock not validly tendered in the tender
offer will be converted into the right to receive the same $47.20
in cash per share, without interest, that was paid in the tender
offer.
Lonza Microbial Control, a new business sector formed by the
acquisition and led by Jeanne Thoma as previously announced, will
provide customers with a complete solutions offer for their
microbial control needs. The new business will be ideally
positioned to increase R&D and product development spending
across its broader product portfolio. Lonza will offer this
complementary range of products and actives to a broader range of
customers in both established and emerging markets.
Stefan Borgas, CEO of Lonza, comments: "After having built the
world's leading pharmaceutical contract manufacturer over the past
years, we as of today, also are the world's leading microbial
control business. This step enhances our global footprint, balances
our currencies and our business models. We have the willingness and
the resources to invest in R&D and applications development for
the benefit of all of our customers."
Promptly after the completion of the merger, Lonza intends to
cause all shares of Arch Chemicals common stock to be delisted from
the New York Stock Exchange (the "NYSE"). Upon completion of the
merger, Arch Chemicals shares will cease to be traded on the NYSE
and Arch Chemicals will no longer have reporting obligations under
the Securities Exchange Act of 1934, as amended.
About Lonza
Lonza is one of the world's leading suppliers to the
pharmaceutical, healthcare and life science industries. Products
and services span its customers' needs from research to final
product manufacture. It is the global leader in the production and
support of active pharmaceutical ingredients both chemically as
well as biotechnologically. Biopharmaceuticals are one of the key
growth drivers of the pharmaceutical and biotechnology industries.
Lonza has strong capabilities in large and small molecules,
peptides, amino acids and niche bioproducts which play an important
role in the development of novel medicines and healthcare products.
In addition, Lonza is a leader in cell-based research, endotoxin
detection and cell therapy manufacturing. Furthermore, the company
is a leading provider of value chemical and biotech ingredients to
the nutrition, hygiene, preservation, agro and personal care
markets.
Lonza is headquartered in Basel, Switzerland and is listed on
the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680
billion. Further information can be found at www.lonza.com.
Forward-looking statements
Forward-looking statements contained herein are qualified in
their entirety as there are certain factors that could cause
results to differ materially from those anticipated. Any statements
contained herein that are not statements of historical fact
(including statements containing the words "believes," "plans,"
"anticipates," "expects," "estimates" and similar expressions)
should be considered to be forward-looking statements. Statements
herein regarding the proposed transaction between Lonza and Arch
Chemicals, the expected timetable for completing the transaction,
the potential benefits of the transaction, and any other statements
about management's future expectations, beliefs, goals, plans or
prospects also constitute forward-looking statements. Investors are
cautioned that all forward-looking statements involve risks and
uncertainty. There are a number of important factors that could
cause actual results or events to differ materially from those
indicated by such forward-looking statements, including:
uncertainties as to the completion of the transaction; the effects
of disruption from the transaction making it more difficult to
maintain relationships with employees, customers, and other
business partners; and changes in the political, social and
regulatory framework in which the company operates, or in economic
or technological trends or conditions, including currency
fluctuations, inflation and consumer confidence, on a global,
regional or national basis. Except as otherwise required by law,
Lonza disclaims any intention or obligation to update any
forward-looking statements as a result of developments occurring
after this communication was made.
CONTACT: Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com
Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com
Arch Chemicals (NYSE:ARJ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Arch Chemicals (NYSE:ARJ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024